Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002022943 | SCV002297895 | uncertain significance | not provided | 2023-07-17 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 334 of the RHOBTB2 protein (p.Gly334Val). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with RHOBTB2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1512261). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Illumina Laboratory Services, |
RCV003408087 | SCV004123261 | uncertain significance | Developmental and epileptic encephalopathy, 64 | 2023-08-02 | criteria provided, single submitter | clinical testing | The RHOBTB2 c.1001G>T (p.Gly334Val) missense variant has not, to our knowledge, been reported in the peer-reviewed literature. This variant is not observed in version 2.1.1 or version 3.1.2 of the Genome Aggregation Database. Based on the available evidence, the c.1001G>T (p.Gly334Val) variant is classified as a variant of uncertain significance for developmental and epileptic encephalopathy. |